Sept. 29, 2016 — Bruce Haynes, founding partner and president of Purple Strategies, will give the keynote address at the Coalition for Healthcare Communication Member Meeting to be held in Washington, D.C., on Nov. 15-16. Haynes works with some of the world’s best-known brands in the areas of strategy and message development, research, advertising, media […]
Read more
Sept. 1, 2016 – In the wake of the agency’s recent settlement with Amarin and other rulings that support the “truthful and non-misleading” communication of unapproved uses, industry has been anxiously awaiting the FDA’s next move, especially after the agency stated in May 2015 that it would hold a hearing on this matter. The wait […]
Read moreJuly 15, 2016 – More than 100 medical associations, including the American Medical Association, signed a letter of support for S. 2978, a bill sponsored by Sen. John Barrasso, M.D. (R-Wyo.), that would exempt peer-reviewed journals, journal reprints, journal supplements, medical conference reports, and medical textbooks from being reported as transfers of value under the […]
Read moreJuly 8, 2016 – As organized medicine, politicians and the public seek to reverse the scourge of opioid addiction, Pfizer made a move that shows a good-faith effort to become a part of the problem’s solution. The company signed an agreement June 30 with the City of Chicago to follow a written code of conduct […]
Read moreApril 25, 2016 — In a speech at the Alliance for a Stronger FDA’s quarterly meeting April 19, new Commissioner of Food and Drugs Dr. Robert M. Califf stated that the agency’s current priorities include determining when advertising is false or misleading and addressing labeling and patient/consumer communication, among others. He also indicated that the […]
Read moreMarch 10, 2016 — The article below, which covers drug pricing concerns in the news and the success of Merck’s Keytruda in treating President Jimmy Carter, is reprinted with permission by The RPM Report. According to Coalition for Healthcare Communication Executive Director John Kamp, “Drug innovation is expensive but worth it. Thank goodness that Jimmy […]
Read moreMarch 3, 2016 – As the FDA fails to update or further clarify its policy regarding off-label promotion, the courts continue to hear cases that are being decided in favor of allowing.S. District Judge Royce Lamberth has entered an order dismissing the case; it is not subject to appeal. companies to share truthful and non-misleading […]
Read moreFeb. 29, 2016 – When faced with criticism of drug pricing, industry members need to be able to defend drug companies, and arming themselves with the facts is a great start, according to Ilyssa Levins, president and founder of the Center for Communication Compliance, who recently posted an article in Pharmaceutical Compliance Monitor. The article, […]
Read moreFeb. 18, 2016 – A bill introduced in the House last week by Rep. Rosa DeLauro (D-Conn.) — the Responsibility in Drug Advertising Act of 2016 (H.R. 4565) – would prohibit direct-to-consumer (DTC) advertising for the first three years following a drug’s approval and allow the Department of Health and Human Services (HHS) to waive […]
Read moreFeb. 8, 2016 – At last week’s House hearing on drug pricing a bipartisan group of U.S. Congressional members, the press and much of the biopharma industry were focused on a public hanging of former Turing Pharmaceuticals CEO Martin Shkreli while the FDA offered quiet but compelling testimony on generic drug approvals. Although the FDA […]
Read more